The maximum recommended dose of Vraylar (cariprazine) is 6 mg once daily for schizophrenia and bipolar mania, and 3 mg once daily for bipolar depression and major depressive disorder. The cap depends entirely on which condition is being treated, and the drug’s unusual behavior in the body makes these limits especially important to understand.
Maximum Dose by Condition
Vraylar is FDA-approved for four conditions, and each has its own dosing ceiling:
- Schizophrenia: 6 mg once daily. Treatment starts at 1.5 mg, can increase to 3 mg on day two, then move up in 1.5 mg or 3 mg steps based on response.
- Bipolar I mania or mixed episodes: 6 mg once daily. Starts at 1.5 mg and increases to 3 mg on day two, with the same step-up options as schizophrenia.
- Bipolar I depression: 3 mg once daily. Starts at 1.5 mg, with the earliest increase to 3 mg on day 15.
- Major depressive disorder (as an add-on to an antidepressant): 3 mg once daily. Same starting dose and timeline as bipolar depression, with the earliest increase on day 15.
The difference matters. For bipolar depression and MDD, the maximum is half of what’s allowed for schizophrenia or mania. Clinical trials tested doses above 6 mg daily (up to 9 and 12 mg) for bipolar mania and found they didn’t work better but did cause more side effects, which is why the FDA capped the dose at 6 mg.
Why the Slow Titration Schedule Matters
Vraylar is not like most psychiatric medications. Its active breakdown products stay in your body far longer than the drug itself. The parent compound has a half-life of roughly 3 to 6 days, but its main active metabolite lingers for 2 to 3 weeks. That means when you take the same dose every day, the total amount of active drug in your system keeps climbing for weeks before leveling off. Between day 1 and day 14 of treatment, total drug exposure increases roughly 25-fold.
This is why the recommended wait before increasing the dose for bipolar depression and MDD is at least 14 days. In clinical trials, patients who had their dose raised faster experienced more side effects. Even for schizophrenia and mania, where the schedule allows quicker increases, the full effect of any dose change won’t show up for several weeks. Side effects that emerge days or even weeks after a dose change can still be related to that adjustment.
Side Effects Increase With Dose
Higher doses of Vraylar come with measurably higher rates of movement-related side effects. In six-week schizophrenia trials, akathisia (an uncomfortable inner restlessness that makes it hard to sit still) affected 9% of people on 1.5 to 3 mg daily compared to 13% on 4.5 to 6 mg. When researchers looked at all movement-related side effects together, the rates were 24% at the lower range and 32% at the higher range.
The pattern was even more pronounced in bipolar mania trials. At 3 to 6 mg daily, 20% of patients experienced akathisia and 41% had some form of movement-related side effect. At the above-recommended doses of 9 to 12 mg, those numbers rose to 21% and 45%, respectively, without meaningful improvement in mania symptoms. This dose-dependent increase in side effects is the main reason the maximum sits where it does.
When the Maximum Dose Is Lower
Certain medications interact with Vraylar in ways that effectively raise the drug’s levels in your body. Vraylar is broken down by a specific liver enzyme, and drugs that block that enzyme slow the process. If you take one of these interacting medications, your prescriber may need to reduce your Vraylar dose below the usual maximum.
Vraylar is also not recommended for people with severe kidney impairment or severe liver impairment, because it has not been studied in those populations. There are no specific dose reductions published for these groups; the drug is simply not advised.
Available Capsule Strengths
Vraylar comes in 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules. There is no capsule above 6 mg because that is the absolute ceiling across all approved uses. The capsules are taken once daily, with or without food, and should not be opened or crushed.